Centene Corp (CNC)
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
- Symbol
- CNC
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Market cap
- $30.67B
- 52 week range
- 31.63 - 69.63
Valuation
- Share price
- $62.08 (close of 2026-09-23)
- P/E (TTM)
- -6.02x
- Price to book
- 1.35x
- Price to free cash flow
- 3.43x
- Enterprise value
- $19.71B
- Book value per share
- $45.82
Price performance
| Period | Change |
|---|
| 1 day | -4.48% |
| 5 days | -8.25% |
| 1 month | -4.52% |
| 3 months | -1.68% |
| 6 months | +89.21% |
| Year to date | +50.86% |
| 1 year | +89.56% |
| 3 years | -9.61% |
| 5 years | -0.83% |
| 10 years | +81.10% |
| All time | +4241.26% |
Profitability and growth
- Return on equity
- -33.32%
- Return on invested capital
- -42.36%
- Return on assets
- -8.70%
- Return on capital employed
- -19.03%
- Gross margin
- 8.14%
- Net margin
- -3.82%
- EBITDA margin
- -3.64%
- Revenue growth
- 19.98%
- Net income growth
- -301.94%
- Free cash flow growth
- 981.84%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 29.19%
- Current ratio
- 1.15x
- Net debt to EBITDA
- 4.01x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $174.58B
- Cost of revenue
- $2.67B
- Gross profit
- $14.21B
- EBITDA
- $-6.35B
- Net income
- $-6.67B
- Earnings per share
- $-13.53
- Shares outstanding
- 493.12M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $174.58B | $14.21B | $-6.67B | $-13.53 |
| 2024-12-31 | $145.50B | $17.07B | $3.31B | $6.33 |
| 2023-12-31 | $140.09B | $17.64B | $2.70B | $4.97 |
| 2022-12-31 | $135.48B | $16.92B | $1.20B | $2.09 |
| 2021-12-31 | $117.98B | $14.49B | $1.35B | $2.31 |
| 2020-12-31 | $103.80B | $100.50B | $1.81B | $3.17 |
| 2019-12-31 | $70.36B | $67.90B | $1.32B | $3.19 |
| 2018-12-31 | $56.44B | $54.05B | $900.00M | $2.31 |
| 2017-12-31 | $45.62B | $43.77B | $828.00M | $2.40 |
| 2016-12-31 | $37.58B | $35.72B | $562.00M | $1.76 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 8.14% | -3.82% | -33.32% | -42.36% |
| 2024-12-31 | 11.73% | 2.27% | 12.47% | 7.56% |
| 2023-12-31 | 12.59% | 1.93% | 10.42% | 8.07% |
| 2022-12-31 | 12.49% | 0.89% | 4.97% | 2.12% |
| 2021-12-31 | 12.28% | 1.14% | 5.00% | 3.74% |
| 2020-12-31 | 96.82% | 1.74% | 6.98% | 6.61% |
| 2019-12-31 | 96.50% | 1.88% | 10.44% | 9.22% |
| 2018-12-31 | 95.77% | 1.59% | 8.17% | 8.46% |
| 2017-12-31 | 95.95% | 1.81% | 12.06% | 12.54% |
| 2016-12-31 | 95.04% | 1.50% | 9.51% | 10.83% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $20.32B | $17.35B |
| 2024-12-31 | $16.68B | $18.42B |
| 2023-12-31 | $19.65B | $17.71B |
| 2022-12-31 | $14.39B | $17.94B |
| 2021-12-31 | $14.66B | $18.57B |
| 2020-12-31 | $12.38B | $16.68B |
| 2019-12-31 | $12.99B | $13.64B |
| 2018-12-31 | $6.06B | $6.65B |
| 2017-12-31 | $4.60B | $4.70B |
| 2016-12-31 | $4.43B | $4.65B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $4.32B | $204.00M |
| 2024-12-31 | $-490.00M | $212.00M |
| 2023-12-31 | $7.25B | $216.00M |
| 2022-12-31 | $5.26B | $234.00M |
| 2021-12-31 | $3.29B | $203.00M |
| 2020-12-31 | $4.63B | $281.00M |
| 2019-12-31 | $753.00M | $177.00M |
| 2018-12-31 | $559.00M | $145.00M |
| 2017-12-31 | $1.07B | $135.00M |
| 2016-12-31 | $1.54B | $148.00M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-27
- Consensus EPS estimate
- $0.07
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-28 | Jun/2026 | $0.89 |
| 2026-04-28 | - | - |
| 2026-02-06 | - | - |
| 2025-10-29 | - | - |
| 2025-07-25 | - | - |
| 2025-07-24 | - | - |
| 2025-04-25 | - | - |
| 2025-04-24 | - | - |
Filings and sources
- Company website
- centene.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
UnitedHealth Group Inc (UNH) · CVS Health Corp (CVS) · Elevance Health, Inc. (ELV) · Cigna Group (CI) · Molina Healthcare, Inc. (MOH) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades